NCT02218736: A reported trial by Duke University
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02218736 |
|---|---|
| Title | A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 30, 2015 |
| Completion date | Nov. 1, 2017 |
| Required reporting date | Nov. 1, 2018, midnight |
| Actual reporting date | Nov. 1, 2018 |
| Date last checked at ClinicalTrials.gov | May 26, 2026 |
| Days late | None |